Ocular Therapeutix, Inc. $OCUL Shares Acquired by Profund Advisors LLC

Profund Advisors LLC lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 43.9% in the second quarter, Holdings Channel reports. The firm owned 22,906 shares of the biopharmaceutical company’s stock after purchasing an additional 6,993 shares during the period. Profund Advisors LLC’s holdings in Ocular Therapeutix were worth $213,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in Ocular Therapeutix during the first quarter worth approximately $1,011,000. Deltec Asset Management LLC lifted its holdings in shares of Ocular Therapeutix by 2.9% during the 2nd quarter. Deltec Asset Management LLC now owns 2,794,892 shares of the biopharmaceutical company’s stock valued at $25,937,000 after acquiring an additional 78,519 shares in the last quarter. Truist Financial Corp boosted its position in Ocular Therapeutix by 100.0% during the 2nd quarter. Truist Financial Corp now owns 100,000 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 50,000 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 17.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 893 shares in the last quarter. Finally, Allianz Asset Management GmbH raised its position in Ocular Therapeutix by 63.2% in the second quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 23,700 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Insider Activity at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,494 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $12.04, for a total value of $258,787.76. Following the completion of the sale, the insider directly owned 3,227,244 shares of the company’s stock, valued at $38,856,017.76. The trade was a 0.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Todd Anderman sold 11,132 shares of the stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $12.34, for a total value of $137,368.88. Following the transaction, the insider directly owned 87,568 shares in the company, valued at approximately $1,080,589.12. This represents a 11.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,806 shares of company stock valued at $727,648 in the last 90 days. 2.30% of the stock is currently owned by insiders.

Ocular Therapeutix Price Performance

OCUL stock opened at $11.30 on Monday. The stock’s 50 day moving average is $11.79 and its two-hundred day moving average is $10.65. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $13.85. The company has a market capitalization of $2.41 billion, a PE ratio of -8.83 and a beta of 1.53. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. The business had revenue of $14.54 million during the quarter, compared to the consensus estimate of $14.57 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. Analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OCUL has been the subject of several analyst reports. Wall Street Zen downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Sunday. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 8th. Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Finally, Needham & Company LLC upped their target price on shares of Ocular Therapeutix from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $22.33.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.